Literature DB >> 15382126

Reduced oncotic necrosis in Fas receptor-deficient C57BL/6J-lpr mice after bile duct ligation.

Jaspreet S Gujral1, Jie Liu, Anwar Farhood, Hartmut Jaeschke.   

Abstract

Neutrophils aggravate cholestatic liver injury after bile duct ligation (BDL). Recently, it was suggested that hepatocellular apoptosis might be critical for liver injury in this model. To test the hypothesis that apoptosis could be a signal for neutrophil extravasation and injury, we assessed parameters of apoptosis and inflammation after BDL using 2 different approaches: (1) wild-type and Fas receptor-deficient lpr mice of the C57BL/6J or C3H/HeJ strains, and (2) treatment with the pancaspase inhibitor z-Val-Ala-Asp-fluoromethylketone (z-VAD-fmk)in C3HeB/FeJ mice. After BDL for 3 days, total cell death was estimated to be between 10% and 50% of all cells evaluated. However, less than 0.1% of hepatocytes showed apoptotic morphology in all 3 strains. Processing of procaspase-3, caspase-3 enzyme activities, and immunohistochemical staining for cytokeratin 18 cleavage products indicated no activation of caspases. Real-time reverse-transcriptase polymerase chain reaction analysis revealed increased expression of many inflammatory mediators but no effect on proapoptotic genes. More than 50% of all accumulated neutrophils were extravasated and colocalized with foci of oncotic hepatocytes and chlorotyrosine adducts. z-VAD-fmk treatment had no effect on apoptosis or liver injury after BDL but eliminated apoptosis after galactosamine/endotoxin in C3HeB/FeJ mice. In Fas receptor-deficient lpr mice (C57BL/6J), expression of inflammatory mediators, neutrophil accumulation and extravasation, chlorotyrosine adduct formation, and liver injury were reduced. This protection was not observed in lpr mice of the endotoxin-resistant C3H/HeJ strain. In conclusion, liver injury (oncotic necrosis) after BDL correlated with the severity of the inflammatory response. The minimal amount of apoptosis had no effect on inflammation or on the overall injury.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15382126     DOI: 10.1002/hep.20380

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  36 in total

1.  Cell Death and Prognosis of Mortality in Alcoholic Hepatitis Patients Using Plasma Keratin-18.

Authors:  Benjamin L Woolbright; Brian W Bridges; Winston Dunn; Jody C Olson; Steven A Weinman; Hartmut Jaeschke
Journal:  Gene Expr       Date:  2017-08-03

2.  Critical Factors in the Assessment of Cholestatic Liver Injury In Vitro.

Authors:  Benjamin L Woolbright; Hartmut Jaeschke
Journal:  Methods Mol Biol       Date:  2015

3.  Sustained phosphorylation of Bid is a marker for resistance to Fas-induced apoptosis during chronic liver diseases.

Authors:  Arndt Vogel; Joseph E Aslan; Holger Willenbring; Christian Klein; Milton Finegold; Howard Mount; Gary Thomas; Markus Grompe
Journal:  Gastroenterology       Date:  2006-01       Impact factor: 22.682

4.  NIM811 (N-methyl-4-isoleucine cyclosporine), a mitochondrial permeability transition inhibitor, attenuates cholestatic liver injury but not fibrosis in mice.

Authors:  Hasibur Rehman; Venkat K Ramshesh; Tom P Theruvath; Insil Kim; Robert T Currin; Shailendra Giri; John J Lemasters; Zhi Zhong
Journal:  J Pharmacol Exp Ther       Date:  2008-09-18       Impact factor: 4.030

5.  Contrast-enhanced micro-computed tomography using ExiTron nano6000 for assessment of liver injury.

Authors:  Xiang-Wei Hua; Tian-Fei Lu; Da-Wei Li; Wei-Gang Wang; Jun Li; Zhen-Ze Liu; Wei-Wei Lin; Jian-Jun Zhang; Qiang Xia
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

6.  Bile acid-induced necrosis in primary human hepatocytes and in patients with obstructive cholestasis.

Authors:  Benjamin L Woolbright; Kenneth Dorko; Daniel J Antoine; Joanna I Clarke; Parviz Gholami; Feng Li; Sean C Kumer; Timothy M Schmitt; Jameson Forster; Fang Fan; Rosalind E Jenkins; B Kevin Park; Bruno Hagenbuch; Mojtaba Olyaee; Hartmut Jaeschke
Journal:  Toxicol Appl Pharmacol       Date:  2015-01-28       Impact factor: 4.219

Review 7.  Therapeutic targets for cholestatic liver injury.

Authors:  Benjamin L Woolbright; Hartmut Jaeschke
Journal:  Expert Opin Ther Targets       Date:  2015-10-19       Impact factor: 6.902

8.  Plasma biomarkers of liver injury and inflammation demonstrate a lack of apoptosis during obstructive cholestasis in mice.

Authors:  Benjamin L Woolbright; Daniel J Antoine; Rosalind E Jenkins; Mary Lynn Bajt; B Kevin Park; Hartmut Jaeschke
Journal:  Toxicol Appl Pharmacol       Date:  2013-10-03       Impact factor: 4.219

9.  Lysosomal instability and cathepsin B release during acetaminophen hepatotoxicity.

Authors:  Benjamin L Woolbright; Anup Ramachandran; Mitchell R McGill; Hui-min Yan; Mary Lynn Bajt; Matthew R Sharpe; John J Lemasters; Hartmut Jaeschke
Journal:  Basic Clin Pharmacol Toxicol       Date:  2012-09-25       Impact factor: 4.080

10.  miR-223 Deficiency Protects against Fas-Induced Hepatocyte Apoptosis and Liver Injury through Targeting Insulin-Like Growth Factor 1 Receptor.

Authors:  Ximena V Qadir; Weina Chen; Chang Han; Kyoungsub Song; Jinqiang Zhang; Tong Wu
Journal:  Am J Pathol       Date:  2015-12       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.